Synthesis, 3D-structure and stability analyses of NRPa-308, a new promising anti-cancer agent.

Anti-cancer agents NRP-a308 stability NRPa-308 synthesis Neuropilins

Journal

Bioorganic & medicinal chemistry letters
ISSN: 1464-3405
Titre abrégé: Bioorg Med Chem Lett
Pays: England
ID NLM: 9107377

Informations de publication

Date de publication:
15 12 2019
Historique:
received: 15 07 2019
accepted: 17 09 2019
pubmed: 9 11 2019
medline: 25 9 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

We report herein the synthesis of a newly described anti-cancer agent, NRPa-308. This compound antagonizes Neuropilin-1, a multi-partners transmembrane receptor overexpressed in numerous tumors, and thereby validated as promising target in oncology. The preparation of NRPa-308 proved challenging because of the orthogonality of the amide and sulphonamide bonds formation. Nevertheless, we succeeded a gram scale synthesis, according to an expeditious three steps route, without intermediate purification. This latter point is of utmost interest in reducing the ecologic impact and production costs in the perspective of further scale-up processes. The purity of NRPa-308 has been attested by means of conventional structural analyses and its crystallisation allowed a structural assessment by X-Ray diffraction. We also reported the remarkable chemical stability of this molecule in acidic, neutral and basic aqueous media. Eventually, we observed for the first time the accumulation of NRPa-308 in two types of human breast cancer cells MDA-MB231 and BT549.

Identifiants

pubmed: 31699610
pii: S0960-894X(19)30668-7
doi: 10.1016/j.bmcl.2019.126710
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Neuropilin-1 144713-63-3

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

126710

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Auteurs

Etienne Brachet (E)

Université de Paris, CiTCoM, UMR 8038 CNRS, Faculté de Pharmacie, F-75006 Paris, France.

Aurore Dumond (A)

Centre Scientifique de Monaco, Biomedical Department, 8 quai Antoine Ier, MC-98000, Monaco.

Wang-Qing Liu (WQ)

Université de Paris, CiTCoM, UMR 8038 CNRS & U 1268 INSERM, Faculté de Pharmacie, F-75006 Paris, France; Université de Paris, LCBPT, UMR 8601 CNRS, UFR Biomédicale des Saints-Pères, F-75006 Paris, France.

Marie Fabre (M)

Université Côte d'Azur, ICN, UMR 7272 CNRS, F-06108 Nice, France.

Mohamed Selkti (M)

Université de Paris, CiTCoM, UMR 8038 CNRS, Faculté de Pharmacie, F-75006 Paris, France.

Françoise Raynaud (F)

Université de Paris, LCBPT, UMR 8601 CNRS, UFR Biomédicale des Saints-Pères, F-75006 Paris, France.

Olivier Hermine (O)

INSERM UMR 1163, Laboratory of Cellular and Molecular Basis of Normal Hematopoiesis and Hematological Disorders: Therapeutical Implications, 24 boulevard Montparnasse, F-75015 Paris, France; Université de Paris, Imagine Institute, 24 boulevard Montparnasse, F-75015 Paris, France; CNRS ERL 8254, 24 boulevard Montparnasse, F-75015 Paris, France.

Rachid Benhida (R)

Université Côte d'Azur, ICN, UMR 7272 CNRS, F-06108 Nice, France; Mohamed VI Polytechnic University, UM6P, 43150 BenGuerir, Morocco.

Philippe Belmont (P)

Université de Paris, CiTCoM, UMR 8038 CNRS, Faculté de Pharmacie, F-75006 Paris, France.

Christiane Garbay (C)

Université de Paris, LCBPT, UMR 8601 CNRS, UFR Biomédicale des Saints-Pères, F-75006 Paris, France.

Yves Lepelletier (Y)

INSERM UMR 1163, Laboratory of Cellular and Molecular Basis of Normal Hematopoiesis and Hematological Disorders: Therapeutical Implications, 24 boulevard Montparnasse, F-75015 Paris, France; Université de Paris, Imagine Institute, 24 boulevard Montparnasse, F-75015 Paris, France; CNRS ERL 8254, 24 boulevard Montparnasse, F-75015 Paris, France.

Cyril Ronco (C)

Université Côte d'Azur, ICN, UMR 7272 CNRS, F-06108 Nice, France.

Gilles Pagès (G)

Centre Scientifique de Monaco, Biomedical Department, 8 quai Antoine Ier, MC-98000, Monaco; Université Côte d'Azur, UMR 7284 CNRS and INSERM U 1081, Institute for Research on Cancer and Aging (IRCAN), Centre Antoine Lacassagne, 33 Avenue de Valombrose, F- 06189 Nice, France.

Luc Demange (L)

Université de Paris, CiTCoM, UMR 8038 CNRS, Faculté de Pharmacie, F-75006 Paris, France. Electronic address: luc.demange@parisdescartes.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH